Truist Financial Corp Lowers Stock Position in Ralliant Corporation $RAL

Truist Financial Corp decreased its position in Ralliant Corporation (NYSE:RAL) by 53.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,573 shares of the company’s stock after selling 15,492 shares during the period. Truist Financial Corp’s holdings in Ralliant were worth $594,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of RAL. Manchester Capital Management LLC acquired a new stake in shares of Ralliant during the 2nd quarter valued at about $29,000. Westfuller Advisors LLC acquired a new position in Ralliant in the 3rd quarter worth about $26,000. Evermay Wealth Management LLC purchased a new position in Ralliant during the second quarter worth approximately $32,000. Webster Bank N. A. purchased a new position in Ralliant during the third quarter worth approximately $31,000. Finally, SouthState Corp acquired a new stake in Ralliant in the second quarter valued at approximately $35,000.

Ralliant Price Performance

Shares of NYSE RAL opened at $42.78 on Thursday. The firm has a 50-day simple moving average of $51.11 and a 200-day simple moving average of $46.62. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $4.83 billion and a price-to-earnings ratio of 21.83. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $57.02.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The business had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The business’s revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be given a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Ralliant’s dividend payout ratio is 10.20%.

Key Ralliant News

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Company insiders (directors and an SVP) bought shares this week, signaling management confidence and providing a support signal for some investors. Insider Buying Alert
• Positive Sentiment: Vertical Research upgraded RAL (reported by media), which can attract buyers and help stabilize demand. Vertical Research Upgrade
• Neutral Sentiment: Ralliant will present at Citi and Barclays investor conferences Feb. 17–18 — management may use these forums to clarify impairment drivers and outlook (could reduce uncertainty if handled well). Investor Conference Notice
• Neutral Sentiment: Some sell‑side firms trimmed price targets (Barclays, Citi, Oppenheimer et al.) — mixed analyst adjustments leave consensus still above current levels but reduce near‑term enthusiasm. Analyst Target Moves
• Negative Sentiment: Ralliant disclosed a $1.4B non‑cash goodwill impairment in its Test & Measurement segment and trimmed FY‑2026 guidance — a material accounting charge that directly pressured the stock and prompted analyst downgrades. Impairment / Guidance Notice
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Kessler Topaz, Kaplan Fox, Kirby McInerney, Bragar Eagel & Squire, etc.) have opened investigations into the timing and disclosure around the impairment and dividend — this raises litigation, regulatory and reputational risk. Levi & Korsinsky Alert
• Negative Sentiment: Short interest jumped ~58.7% in January (~3.75M shares, ~3.3% of float), increasing bearish positioning that can amplify downside and intraday volatility.
• Negative Sentiment: Independent downgrades (e.g., Zacks strong‑sell, Weiss Ratings cut) add selling pressure and can limit buyers until uncertainty eases. Zacks

Insider Buying and Selling

In related news, Director Anelise Angelino Sacks bought 2,000 shares of the business’s stock in a transaction on Monday, February 9th. The stock was acquired at an average cost of $41.25 per share, with a total value of $82,500.00. Following the purchase, the director directly owned 5,403 shares of the company’s stock, valued at $222,873.75. The trade was a 58.77% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Amir A. Kazmi purchased 2,545 shares of Ralliant stock in a transaction dated Friday, February 6th. The shares were bought at an average price of $39.27 per share, for a total transaction of $99,942.15. Following the acquisition, the senior vice president owned 39,699 shares in the company, valued at approximately $1,558,979.73. This trade represents a 6.85% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have purchased 5,795 shares of company stock worth $232,405.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Oppenheimer reduced their target price on Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, February 6th. Vertical Research upgraded shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research report on Friday, February 6th. Citigroup dropped their target price on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Zacks Research downgraded shares of Ralliant from a “hold” rating to a “strong sell” rating in a research report on Monday. Finally, Truist Financial decreased their price target on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $50.50.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.